D
DIAMEDICA THERAPEUTICS INC
NASDAQ: DMAC (DiaMedica Therapeutics Inc.)
Last update: 3 hours ago4.06
0.01 (0.25%)
| Previous Close | 4.05 |
| Open | 4.00 |
| Volume | 80,803 |
| Avg. Volume (3M) | 91,461 |
| Market Cap | 174,107,008 |
| Price / Book | 4.50 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 - 11 Aug 2025 |
| Diluted EPS (TTM) | -0.600 |
| Total Debt/Equity (MRQ) | 0.83% |
| Current Ratio (MRQ) | 8.28 |
| Operating Cash Flow (TTM) | -22.08 M |
| Levered Free Cash Flow (TTM) | -11.68 M |
| Return on Assets (TTM) | -33.18% |
| Return on Equity (TTM) | -53.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | DiaMedica Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.13 |
|
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 15.65% |
| % Held by Institutions | 34.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Omega Advisors Inc. | 31 Mar 2025 | 1,625,000 |
| First Manhattan Co. Llc. | 31 Mar 2025 | 606,435 |
| Paragon Associates & Paragon Associates Ii Joint Venture | 31 Mar 2025 | 600,000 |
| Bleichroeder Lp | 31 Mar 2025 | 382,317 |
| Lpl Financial Llc | 31 Mar 2025 | 155,300 |
| 52 Weeks Range | ||
| Median | 10.00 (146.31%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Mar 2025 | 10.00 (146.31%) | Buy | 5.24 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |